產(chǎn)品基本信息
產(chǎn)品編號(hào)：D535500
產(chǎn)品名稱：DOTA
產(chǎn)品CAS：60239-18-1
規(guī)格含量：250mg
產(chǎn)品價(jià)格：面議
聯(lián)系我們:
產(chǎn)品詳細(xì)介紹
標(biāo)準(zhǔn)品編號(hào):
D535500
名稱:
DOTA
別名:
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid; 1,4,7,10-Tetra(carboxymethyl)-1,4,7,10-tetraazacyclododecane; 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid; DOTA; NSC 681107; Tetraxetan
CAS號(hào):
60239-18-1
分子式:
C??H??N?O?
外觀:
白色至白色固體
熔點(diǎn):
>225°C (dec.)
分子量:
404.42
儲(chǔ)存:
Hygroscopic, 冰箱保存, Under Inert Atmosphere
溶解度:
Water (Slightly), Methanol (Slightly)
種類:
Building Blocks; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
Bifunctional DOTA aconjugates to peptides and has become an established strategy for constructing target-specific metal containing agents including targeted MRI contrast agents and diagnostic and therapeutic radiopharmaceuticals.
參考文獻(xiàn)
Lewis, M., et al.: Bioconjug. Chem., 9, 72 (1998), Chappell, L., et al.: Bioorg. Med. Chem., 7, 2313 (1999), Prantner, A., et al.: Mol. Imaging, 2, 333 (2003), Allen, M., et al.: Chem. Biol., 11, 301 (2004), Weiner, R., et al.: BioDrugs, 19, 145 (2005), Breeman, W., et al.: Radionuclide Peptide Cancer Therapy, 119 (2006),
?您的位置：
